AP-121 (Aestas Pharma)

N/A

Report date: 2025/06/11 10:56:58

Base Information

Drug NameAP-121 (Aestas Pharma)
Drug Alias NameAP-121 (Aestas Pharma)AP-PEP31TFP-5
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionBeta amyloid A4 protein aggregation inhibitorsNeuroprotectantsCyclin-dependent kinase 5 inhibitors +[4] 
TargetsCyclin-dependent kinase 5Microtubule-associated protein tauBeta amyloid A4 protein
Therapy Area/IndicationsAlzheimer DiseaseParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNational Institute Of Neurological Disorders And Stroke
China Registration ClassN/A

Develop Information

Active CompaniesAestas Pharma Inc
Inactive CompaniesNational Institutes Of HealthNational Institute Of Neurological Disorders And Stroke
Active IndicationsAlzheimer DiseaseParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A